← Evidence map

ArticleTargeted oncology2026

Real-World Outcomes of Sequential Afatinib and Osimertinib Versus Afatinib and Chemotherapy in EGFR-Mutant NSCLC: Taiwan Multicenter GIANT Study.

How-Wen Ko et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

Not cited yet

Real-World Outcomes of Sequential Afatinib and Osimertinib Versus Afatinib and Chemotherapy in EGFR-Mutant NSCLC: Taiwan Multicenter GIANT Study. | OpenQuestion